Irish healthcare R&D gets Euro10m boost:
This article was originally published in Clinica
Executive Summary
Ireland's Health Research Board has been awarded Euro10m ($12.3m) capital funding in 2005, taking its annual revenue budget to Euro27m, up more than 300% since 1999. The allocation seeks to support the recommendations of a 2001 health research strategy report, highlighting the importance of improving R&D in increasing the effectiveness and efficiency of Ireland's health service.
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.